| 王利平,高有方.恩替卡韦联合胸腺肽α1治疗慢性乙型肝炎的疗效观察[J].安徽医药,2018,22(5):944-946. |
| 恩替卡韦联合胸腺肽α1治疗慢性乙型肝炎的疗效观察 |
| Therapeutic effect of Entecavir combined with Thymosin α1 for chronic hepatitis B |
| 投稿时间：2016-08-31 |
| DOI： |
| 中文关键词: 慢性乙型肝炎 胸腺肽α1 恩替卡韦 疗效 |
| 英文关键词: chronic hepatitis B thymosin α1 entecavir therapeutic effect |
| 基金项目: |
|
| 摘要点击次数: 2191 |
| 全文下载次数: 580 |
| 中文摘要: |
| 目的 探索恩替卡韦联合胸腺肽α1治疗慢性乙型肝炎(CHB)的疗效。 方法 将58例HBeAg阳性慢性乙型肝炎患者采用随机数字表法分为观察组29例和对照组29例。观察组采用恩替卡韦联合胸腺肽α1治疗,对照组采用恩替卡韦治疗,治疗48周进行疗效评价。比较两组患者ALT复常率、AST复常率、HBsAg阴转率、HBeAg阴转率、HBeAg/HBeAb血清学转换率、HBV DNA阴转率和不良反应的差异。 结果 治疗48周末,观察组ALT复常率(93.10%)、AST复常率(96.55%)、HBsAg阴转率(10.34%)、HBeAg阴转率(51.72%)、HBeAg/HBeAb血清学转换率(31.03%)、HBV DNA阴转率(82.76%)均高于对照组,其中HBeAg阴转率、HBV DNA阴转率、ALT复常率、HBeAg/HBeAb血清学转换率差异有统计学意义(P<0.05)；但是AST复常率、HBsAg阴转率差异无统计学意义(P>0.05)。 结论 恩替卡韦联合胸腺肽α1治疗慢性乙型肝炎较单用恩替卡韦有较显著疗效,并且能提高慢乙肝患者HBeAg、HBV DNA阴转率,且未增加不良反应,安全性较高。 |
| 英文摘要: |
| Objective To investigate the curative effect of Entecavir combined with Thymosin α1 for chronic hepatitis B. Methods Fifty-eight patients with chronic hepatitis Bin The PeopIe′s HospitaI of Bozhou were randomly assigned into treatment group (n=29) and control group (n=29).Treatment group was given Entecavir combined with Thymosin α1 while control group was given Entecavir for 48 weeks.The differences in negative conversion rate of HBsAg,negative conversion rate of HBeAg,conversion rate of HBeAg/anti-HBe serum,negative conversion rate of HBV DNA,renormalization rate of ALT and AST,and adverse reactions between two groups were compared. Results After 48 weeks of treatment,for patients in treatment group,the renormalization rate of ALT (93.10%) and AST (96.55%),negative conversion rate of HBsAg (10.34%),negative conversion rate of HBeAg (51.72%),conversion rate of HBeAg/anti-HBe serum (31.03%),negative conversion rate of HBV DNA (82.76%) were higher than those in control group.The changes of negative conversion rate of HBeAg and HBV DNA,recovery rate of ALT,conversion rate of HBeAg/anti-HBe serum of patients in both groups had statistical differences (P<0.05),while the recovery rate of AST,negative conversion rate of HBeAg,and adverse reactions had no significant differences (P>0.05). Conclusions Entecavir combined with Thymosin α1 in treatment of chronic hepatitis B,compared with entecavir alone,has significant clinical curative effect,which can improve negative conversion rate of HBeAg and HBV DNA,and does not increase adverse reactions with high safety. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
